IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 12124 
Small font sizeDefault font sizeIncrease font size
Navigate Here
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »  Article in PDF (1,304 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

In This Article
 »  Abstract
 » Introduction
 »  Materials and Me...
 »  Results and Disc...
 » Conclusion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    PDF Downloaded317    
    Comments [Add]    
    Cited by others 30    

Recommend this journal


 Table of Contents    
Year : 2020  |  Volume : 52  |  Issue : 2  |  Page : 142-149

Update on the target structures of SARS-CoV-2: A systematic review

1 Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Biophysics, Postgraduate Institute of Medical Education and Research, Chandigarh, India
3 Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India

Date of Submission21-Apr-2020
Date of Decision15-May-2020
Date of Acceptance18-May-2020
Date of Web Publication3-Jun-2020

Correspondence Address:
Bikash Medhi
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijp.IJP_338_20

Rights and Permissions

 » Abstract 

Knowledge of structural details is very much essential from the drug-design perspective. In the systematic review, we systematically reviewed the structural basis of different target proteins of SARS-corona virus (CoV2) from a viral life cycle and from drug design perspective. We searched four literature (PubMed, EMBASE, NATURE, and Willey online library) databases and one structural database (RCSB.org) with appropriate keywords till April 18, and finally, 26 articles were included in the systematic review. The published literature mainly centered upon the structural details of “spike protein,” “main protease/M Pro/3CL pro,” “RNA-dependent RNA polymerase,” and “nonstructural protein 15 Endoribonuclease” of SARS-CoV-2. However, inhibitor bound structures were very less. We need better structures elucidating the interactions between different targets and their inhibitors which will help us in understanding the atomic level importance of different amino acid residues in the functionality of the target structures. To summarize, we need structures with fine resolution, co-crystallized structures with biologically validated inhibitors, and functional characterization of different target proteins. Some other routes of entry of SARS-CoV-2 are also mentioned (e.g., CD147); however, these findings are not structurally validated. This review may pave way for better understanding of SARS-CoV-2 life cycle from structural biology perspective.

Keywords: COVID-19, drug target, life cycle, SARS-corona virus-2, target structures

How to cite this article:
Prajapat M, Sarma P, Shekhar N, Prakash A, Avti P, Bhattacharyya A, Kaur H, Kumar S, Bansal S, Sharma AR, Medhi B. Update on the target structures of SARS-CoV-2: A systematic review. Indian J Pharmacol 2020;52:142-9

How to cite this URL:
Prajapat M, Sarma P, Shekhar N, Prakash A, Avti P, Bhattacharyya A, Kaur H, Kumar S, Bansal S, Sharma AR, Medhi B. Update on the target structures of SARS-CoV-2: A systematic review. Indian J Pharmacol [serial online] 2020 [cited 2023 Sep 28];52:142-9. Available from: https://www.ijp-online.com/text.asp?2020/52/2/142/285728

FNx01Equal contribution between Phulen Sarma and Manisha Prajapat

 » Introduction Top

SARS-corona virus (CoV-2) is the newest member of a large group of viruses coming under the order Nidovirales and family coronaviridae and genera beta coronavirus (group 2B).[1] SARS-CoV-2 consists of four basic structural proteins, which are club shape trimeric “spike protein (S)”, “membrane (M) protein”, “envelop (E) protein,” and helically symmetrical “nucleocapsid protein (N).”[2]

The molecular basis of transmission of coronavirus (CoV) is already explained in our previous systematic review.[3] The infection process starts with the binding of the spike protein S1-domain to the human host cell receptor angiotensin-converting enzyme 2 (ACEs), which leads to conformational change in the S1 and S2 domain of spike protein. These changes expose the “fusion peptide” of S2-domain, which mediates the fusion of the viral and host cell membranes. The RNA genome of the virus is then subsequently released into the host cell. The virus uses host-cell machinery to start the translation process to synthesize necessary polyproteins such as a pp1a, pp1ab which are further processed by proteases to release the nonstructural viral proteins (NSPs). The structural proteins (spike, E, N, and M protein) are translated from their respective location in the viral genome. The synthesized structural proteins, nonstructural proteins, and RNA genome assembles, which is then transported outside the cell by exocytosis.[4]

Coming to the presently available pharmacotherapeutic options for the treatment of COVID-19, chloroquine, hydroxychloroquine,[5] interferon-α, ribavirin, corticosteroids,[3] plasma therapy,[6] intravenous immune-globulins,[7] lopinavir/ritonavir, etc., are the mainstream treatment options; however, most of the agents are being used without major clinical evidence of efficacy and safety. Although many therapeutic options are under evaluation in different settings, for example, in silico, in vitro, preclinical, and clinical studies, however, definite evidence of efficacy of any of the agents in clinical settings is still not clear.[2],[3],[5],[8]

SARS-CoV-2 is 70%–80% similar to SARS-CoV at the genomic level.[9] Recent studies highlighted many important genomic variations in SARS-CoV-2, for example, the absence of 8a protein, changes in number of amino acid in 3c and 8b protein.[4] The spike protein is also modified by the homologous recombination process.[10] As compared to SARS-CoV, a mutation (N501T) in the spike protein of SARS-CoV-2 confers higher-binding affinity of SARS-CoV2 to the ACE2 receptor.[11]

Better understanding the viral life cycle in terms of structural biology perspectives can help us in identifying druggable targets, which can be approached from drug design perspective. Here, we systematically reviewed the available target protein structures of SARS-CoV2 in relation to the viral life cycle and drug-design perspective.

 » Materials and Methods Top

We screened five literature database (PubMed, Embase, Nature, Willey online library, and RCSB database), using the keywords “crystal structure,” “NMR structure,” “X-Ray structure,” “COVID-19,” 2019-nCoV, SARS-CoV-2, “2019 novel corona virus” till April 18. At first titles and abstracts were screened, which was followed by full-text screening of the relevant articles as per the predefined inclusion/exclusion criteria for possible inclusion.

Inclusion-exclusion criteria

We included peer-reviewed published studies evaluating target protein three-dimensional (3D) structure (nuclear magnetic resonance, X-ray crystallography and cryo-electron microscopy structure) with or without bound ligand, with structures deposited and published in RCSB.org. Among unpublished studies with structure published in RCSB.org, we included only inhibitor bound structures.

 » Results and Discussion Top

A total of 206 nonduplicate studies were found after the preliminary screening of the databases. After title and abstract screening, a total of 55 studies were selected for further full-text screening. Among these 55 articles, 29 articles were excluded (review articles = 6, articles addressing SARS-CoV = 7, articles addressing MERS-CoV = 11, guideline = 1, in silico drug designing studies without intricate details of SARS-CoV-2 = 4). A total of 26 studies fulfilling the inclusion/exclusion criteria were included in the final review. The PRISMA flowchart of the study is shown in [Figure 1]. Details of published studies with important structural and functional target proteins are summarized in [Table 1]. Details of the important inhibitor-bound target structures without a peer-reviewed publication of the respective study are shown in [Table 2].
Figure 1: PRISMA flow chart of the study

Click here to view
Table 1: Important PDB structures with published study details in peer-reviewed journal

Click here to view
Table 2: All available XRD structure with Co-crystallized ligand which are not published till date

Click here to view

Target structures of COVID-19

After reviewing the full text of the articles, we could find published papers with 3D structures of only four targets, which are spike protein, main protease (also known as main protease [Mpro] and 3CLpro), RNA-Dependent RNA-Polymerase (RdRP), and NSP15 of SARS CoV-2.

Spike protein

The spike proteins are trimeric fusion proteins, with two main domains, the S1 and the S2 domain. The structure the spike protein of SARS-CoV2 is around 77% conserved when compared to SARS-CoV.[12] Root mean square deviation (RMSD) between SARS-CoV receptor-binding domain (RBD) and SARS-CoV-2 RBD is around 1.2 angstrom and RMSD between receptor-binding motif (RBM) of SARS-CoV and RBM of SARS-CoV-2 is around 1.3 angstrom, implicating high similarity between these two structures.[13] The affinity of interaction between ectodomain of SARS-CoV-2 and ACE-2 is very high (10–20 fold) as compared to SARS-CoV, and thus, it contributes to the high infectivity SARS-CoV-2.[14]

The spike proteins are considered as a class-1 viral fusion-protein, and it requires two-step protease cleavages for activation. The site between S1 and S2 is the location of priming cleavage; however, the activation cleavage occurs solely on S2. Different protease, for example, trans-membrane protease serine protease-2 (TMPRSS-2), TMPRSS-4, human airway trypsin (HAT) like protease, cathepsins, etc., are involved in these proteolytic activation process. In cell-based experiments (293/hACE2 cells), the expression of different TMPRSS iso-forms enhanced SARS-CoV-2 spike protein-mediated cell-cell fusion.[15]

Importance of S1 domain

The S1-RBD-mediated recognition and attachment to the host receptor (ACE2) is a prime-initiating event, which leads to viral and host-cell fusion and other subsequent events. This highlights the importance of detailed understanding of the interactions between the S1 domain of spike protein and ACE2.

Details of S1 domain and its interaction with angiotensin-converting enzyme 2

The RBD of the S1-spike protein of SARS-CoV-2 consists of a core region and the receptor-binding motif (RBM).[16] The Core region consists of 5 beta-pleated sheets (1, 2 3, 4, and 7), which are organized in the antiparallel mode. The RBM consists of two short beta-pleated sheets (β5 and β6), loops and alpha helices (alpha 4 and 5). A total of three cysteine residue pairs provide stability to the core and another cysteine residue pair helps in connecting the distal end of RBM.[13] However, the interacting surface between the S1 RBD and ACE2 is quite huge (total buried surface area of 1687 angstraon[2] with around 800 Š each on the S1 RBD side and ACE2 side).[13] Compared to SARS-CoV, many variations were seen in the SARS-CoV RBD region, for example, in the N terminal, the variations ARG426 to ASN 439, TYR484 to GLN498, and THR487 to ASN50 were observed between SARS-CoV and novel SARS-CoV2.[17]

S1 domain of spike protein and its interaction with peptidase domain of ACE2

ACE2 also serves as a chaperone to the amino acid transporter Bo At1 (SLC6A19). A full length structure of ACE2-Bo At1 complex is already reported. The complex represent a homodimer (2× [ACE2-Bo At1]) of two heterodimers (ACE2-Bo At1), exhibit closed or open conformation due to shift of the peptidase domain (PD) of ACE2. However, the homo-dimerization is mediated by the collectrin like domain (CLD).[18] Interestingly, the open close conformation of the complex is governed by the state of the peptidase domain of the ACE2. The peptidase domain also binds to the S1 domain of spike protein. A dimeric ACE2 complex can accommodate two S proteins together. These interactions may play an important role in membrane invagination during endocytosis. However, ACE2 may stay as homodimer even in the absence of Bo AT1.[18] PDB I. D. 6M17 represents a cryo-EM Structure ACE-2 (amino acids 814) in the presence of the transporter B0AT1 with and without RBD of “SARS-COV-2-spike protein” (resolution of 2.9 angstroms).[18] The structure of “spike-protein RBD” in complex with “ACE2-BoAT complex” is shown in [Figure 2].
Figure 2: Structure of ACE-2 receptor with RBD region of S protein. Abbreviations: RBD = Receptor-binding domain of SARS-corona virus-2, PD = Peptidase domain of ACE2, CLT = Collectrin-like domain, BOAT1 = Sodium-dependent neutral amino acid transported B(o)AT1

Click here to view

The PD of ACE2 is the main region responsible for its interaction with the spike protein (dissociation constant [Kd] of ~15 nM).[17] The major interactions being H bond between RBD (Gln498, Thr500, and Asn501) with N terminal of ACE-2 (Tyr41, Gln42, Lys353, and Arg357), TYR453 and LYS417 of RBD region bind with middle of the bridge region of ACE2 (Asp30 and His34), hydrogen bond forms in between Gln474 residues of RBD and Gln24 residues of C terminal of ACE2. Phe486 of the RBD shows van-der Waal force interaction with Met 82 of ACE-2.[17]

S2 domain

The S2 subunit has a key role in the membrane fusion.[19] The homology between S2 segments of SARS-CoV and SARS-CoV-2 is around 89%.[20] The fusion process is initiated by the initial interactions between the RBD of spike S1 domain of SARS-CoV-2 and the PD of ACE2.[20] This process is followed by the interaction between heptad repeat1 (HR1) and heptad repeat2 (HR2) domain of S2 to form a six helix bundle fusion core, which fuses with the host cell membrane.[21] Compared to SARS-CoV-2, an eight residue sequence in the fusion region of S2 of SARS-CoV-2 imparts more stability to the six helix bundle core.[22] An already established pan CoV inhibitor EK1 was also found to be useful against SARS-CoV-2. By conjugating cholesterol with the EK1, a new molecule was designed (EK1C4), which showed more potent inhibitory action against SARS-CoV-2.[23]

Compared to SARS-CoV, the host membrane fusion ability is higher in the case of SARS-CoV-2. Few mutated amino acids in the HR1 results in enhanced interaction with the HR2 domain.[22] Details of interaction between HR1 and HR2 of S2 can be visualized in the PDB: 6 LXT.[22]

Role of fusion peptide of S2

The S2 domain contains two heptad repeats (HR1 and HR2) and one fusion peptide. In case of SARS-CoV, critical cleavage at R797 may expose the viral fusion peptide.[24] This fusion peptide-associated fusion platform (bipartite) alters the membrane integrity in the presence of calcium.[25] A proteolytic cleavage in the S2 exposes the fusion peptide. In virology, fusion peptides are used as the mediators for the fusion process as they help lipid membranes to fuse and permeabilize. In case of SARS-CoV-2, two fusion peptides are recognized that is SARSww-I and SARSww-II at the N terminal region of spike protein of nCoV. However, among these, only SARSww-I peptide robustly divided into the membranes of large unilamellar vesicles and induced the fusion of lipid vesicles causing vesicular aggregation and induced the leakage of lipid vesicles (an indicator of the propensity to perturb membrane integrity).[26]

In another experiment, treatment with bafilomycin or ammonium chloride decreased the SARS-CoV-entry to 293/hACE2 cells indicating endocytosis as the possible route of establishment of cellular infection. Some phosphoinositides may play an important role in this endocytosis process, for example, phosphatydleinositol 3-phosphate 5 kinase (PIPKIN) which plays a major role in the synthesis of phosphotydilinositol 3,5 bis phosphate in early endosome. Inhibiting PIPKIN with apilimod resulted in the decreased entry of SARS-CoV-2 spike pseudo-virion into 293/hACE2 cells. However, in the downstream, TCP2 was found to be another major determinant in the SARS-CoV-2 endocytosis process.[15]

Details of published target structures of S1 and S2

After searching the RCSB database, we could find eight structures of spike protein S1 and S2 domain, of which respective study was also published in a peer reviewed journal. However, we could find few structures, of which details were not available in the peer reviewed domain. However, among these structures, we could find one structure (PDB I. D. 6W41) in which RBD of S1 of SARS-CoV-2 was co-crystallized with a neutralizing antibody (isolated from convalescent SARS-CoV patients).[12] The PDB I. D. 6VW1 represents SARS-CoV-2 chimeric RBD crystallization structure complex.[16] The structures 6VXX and 6VYB represent the SARS-CoV-2 S ectodomain trimer both in both closed and open states. The PDB I. D. 6VSB represents a high-resolution structure (cryo EM) of the spike protein (3.46 Š) with sequence length of 1288 amino acids.[14] The PDB I. D. 6M0J represents a crystal structure of RBD region of spike protein (S) bound to the ACE2 receptor at the resolution of 2.45 Š.[13] Again, some of the polyclonal antibodies against spike protein of SARS-CoV also neutralized SATRS-CoV-2, indicating that the conserved regions of the S epitopes can be targeted for developing a vaccine.[27] However, three SARS-CoV specific antibodies failed to bind against the spike protein of SARS-COV-2.[14]


The replicase gene of SARS-CoV-2 encodes two polyproteins (pp1a and pp1ab), which are necessary for replication/transcription process of the virus.[20],[28],[29] The Main protease and the papain-like protease are the two major proteases, which processes these two polyproteins to release 16 nonstructural proteins (NSPs) of polyproteins which results from translation of viral RNA.[28]

Main protease/MPro/3CL pro

The structure typically contains two protomers (protomer I and II), each of which consisting of 3 domains (domain I, II and III), with around 100 amino acids in each domain. The substrate-binding site residues in the gap between I and II domain. One interesting feature is that the substrate binding site is highly conserved among all SARS-CoV Main protease and the most variable domain being helical domain III.[30] In domain III, five helices cluster is located which implicated in dimerization of Mpro through a salt bridge interaction (Arg-4 of one protomer and Glu-290 of the other protomer). For the catalytic activity, the dimerization is necessary because the N-finger of each protomer interacts with the other protomer through its interaction with residues Glu166 and thus helps to form the shape of the substrate binding site.[28] The structure of the main protease is represented in [Figure 3].
Figure 3: Structure of main protease. Each protomer consists of three domains containing approximately 100 amino acid residues in each. The substrate binding site resides in the cleft between domain I and II. Domain II and III is linked by a long loop

Click here to view

M pro has ability to cleave the larger pp1ab at particular 11 sites; The recognition site being leu-gln*-*ser-ala-gly in most of the cases.[28]

The Mpro crystal structure with an inhibitor (N3) is already reported (PDB I. D. 6 LU7).[30] Structure of SARS-CoV-2 Mpro is reported with α-ketoamide inhibitor (PDB: 6Y2E,6Y2G,6Y2F).[28]

Nonstructural proteins

The genomic organization of COVID-19 contains 5' UTR, orf-1ab, S, E, M, N gene and UTR 3'. Among them, ORF1ab cover the largest part of viral genome and is responsible for coding of 16 NSP nonstructural-proteins (1-16).[31] NSP3 and NSP 5 encodes the “papain like protease (PL pro)” and “chymotrypsin-like protease (CL Pro or M Pro)” respectively, while NSP15 shows endo-ribonulease activity.[32]

ORF1b encoded NSPs (12–16) are involved in RNA replication/transcription process. These NSPs e.g., RdRp and helicase complex comprises the replication transcription complex (RTC).[32],[33] These RTC are typically anchored in endoplasmic reticulum (ER) originated double membrane containing vesicles which are further integrated into convoluted membranes (network of modified ER membrane).[33]

Nonstructural protein 15

Among the all SARS-CoV-2 NSP, the only available crystal-structure of is of NSP15 (PDB I. D. 6VWW, 371 amino acid, 2.20 Š).[34] However, none of the structures of NSP 15 were inhibitor bound. NSP15 belongs to the endoribonuclease (EndoU) family,[35] which play role in RNA processing. NSP15 is an essential element in the coronavirus life cycle.[36] Nsp15 is an endoribonuclease nidoviral RNA uridylate-specific (NendoU), belonging to the EndoU family. The C-terminal-NendoU domain is responsible for the catalytic-function of Nsp15. The active site present in between 2 B sheet, which comprises of six conserved residues HIS235, LY290, HIS250, THR341, SER294, TYR343.[36] NendoU activity of the Nsp15 can induce protein-interference in the innate-immune response, however, this effect may be independent of the endonuclease activity also. NSP-15 is a necessary element in the life cycle of for coronavirus.[36]

RNA-dependent RNA-polymerase

NSP12 also known as a RdRp is a key component in viral life cycle, which plays an essential role in synthesis of viral RNA and transcription/replication. NSP7 and NSP8 act are required cofactors for this machinery.[37]

The NSP12 structures comprises of the NiRAN domain towards the N terminal end and the RdRp domain toward the C terminal end.[38] NiRAN domain and polymerase domain are Linked by an interface domain.[39] The complex structure of RdRP is depicted in [Figure 4].
Figure 4: Structure of RNA-dependent RNA-polymerase in complex with nonstructural protein -7 and 8. Nonstructural protein 8 and nonstructural protein 7 are the necessary co-factors of nonstructural protein -12. The NiRAN domain and the polymerase domain of the nonstructural protein 12 complex are connected by an interface. A beta-hairpin structure resides in the N terminal domain

Click here to view

Nsp12 is thought to be a primary target of nucleotide analogues such as remdesvir (antiviral inhibitor), which has the ability to treat SARS-CoV-2 viral infection.[40] A cryo EM structure of NSP12 with remdesvir is reported in complex with triphosphate form of remdesvir, NSP-7 and NSP-8 (PDB I. D. 7BV2, 2.9-Š resolution),[41] in presence and absence of DTT.[39]

 » Conclusion Top

Detailed knowledge biological interactions are of utmost importance while designing new drugs or in case of virtual screening of ligand databases against particular target. We have structures of most of the SARS-CoV-2 targets; however, we don't have crystallized structure of few NSPs and few structural proteins yet. We need more structural details to understand the atomic level importance of different targets proteins and their interactions with inhibitors, which may pave way for the development of safe and effective anti-COVID-19 therapy.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

 » References Top

Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1-23.  Back to cited text no. 1
Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, et al. Drug targets for corona virus: A systematic review. Indian J Pharmacol 2020;52:56-65.  Back to cited text no. 2
Sarma P, Prajapat M, Avti P, Kaur H, Kumar S, Medhi B. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol 2020;52:1-5.  Back to cited text no. 3
  [Full text]  
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:91-8.  Back to cited text no. 4
Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis. J Med Virol 2020; doi:10.1002/jmv.25898.  Back to cited text no. 5
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020;20:398-400.  Back to cited text no. 6
Díez J-M, Romero C, Gajardo R. Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens. Immunotherapy 2020; DOI: 10.2217/imt-2020-0095.  Back to cited text no. 7
Sarma P, Shekhar N, Prajapat M, Avti P, Kaur H, Kumar S, et al. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain). J Biomol Struct Dyn 2020; p. 1-9. doi:10.1080/07391102.2020.1753580.  Back to cited text no. 8
Ceccarelli M, Berretta M, Rullo EV, Nunnari G, Cacopardo B. Editorial – Differences and Similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a Rose by Another name Smell as Sweet Eur Rev Med Pharmacol Sci 2020;24(5):2781-3. doi:10.26355/eurrev_202003_20551.  Back to cited text no. 9
Discovery of Bat Coronaviruses through Surveillance and Probe Capture-Based Next-Generation Sequencing mSphere. Available from: https://msphere.asm.org/content/5/1/e00807-19.abstract. [Last accessed on 2020 Apr 26].  Back to cited text no. 10
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS Coronavirus. J Virol 2020;94:e00127-20. DOI: 10.1128/JVI.00127-20.  Back to cited text no. 11
Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 2020;368:630-3.  Back to cited text no. 12
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581:215-20.  Back to cited text no. 13
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260-3.  Back to cited text no. 14
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 2020;11:1620.  Back to cited text no. 15
Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020;581:221-4.  Back to cited text no. 16
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020;367:1444-8.  Back to cited text no. 17
Yan R, Zhang Y, Li Y, Xia L, Zhou Q. Structure of dimeric full-length human ACE2 in complex with B0AT1. bioRxiv 2020. [Preprint].  Back to cited text no. 18
Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, et al. Pre-fusion structure of a human coronavirus spike protein. Nature 2016;531:118-21.  Back to cited text no. 19
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.  Back to cited text no. 20
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection Inhibition Using Spike Protein Heptad Repeat-Derived peptides PNAS. Available from: https://www.pnas.org/content/101/22/8455. [Last accessed on 2020 Apr 26].  Back to cited text no. 21
Inhibition of SARS-CoV-2 (previously 2019-nCoV) Infection by a Highly Potent Pan-Coronavirus Fusion Inhibitor Targeting its Spike Protein that Harbors a high Capacity to Mediate Membrane Fusion Cell Research. Available from: https://www.nature.com/articles/s41422-020-0305-x. [Last accessed on 2020 Apr 20].  Back to cited text no. 22
Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 2020;30:343-55.  Back to cited text no. 23
Madu IG, Belouzard S, Whittaker GR. SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion. Virology 2009;393:265-71.  Back to cited text no. 24
Lai AL, Millet JK, Daniel S, Freed JH, Whittaker GR. The SARS-CoV fusion peptide forms an extended bipartite fusion platform that perturbs membrane order in a calcium-dependent manner. J Mol Biol 2017;429:3875-92.  Back to cited text no. 25
Sainz B Jr., Rausch JM, Gallaher WR, Garry RF, Wimley WC. Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein. J Virol 2005;79:7195-206.  Back to cited text no. 26
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020;181:281-920.  Back to cited text no. 27
Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020;368:409-12.  Back to cited text no. 28
A New Coronavirus Associated with Human Respiratory Disease in China Nature. Available from: https://www.nature.com/articles/s41586-020-2008-3. [Last accessed on 2020 Apr 26].  Back to cited text no. 29
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of mpro from COVID-19 virus and discovery of its inhibitors. Nature 2020. doi: 10.1038/s41586-020-2223-y. [Online ahead of print].  Back to cited text no. 30
da Silva SJ, da Silva CT, Mendes RP, Pena L. Role of nonstructural proteins in the pathogenesis of SARS-CoV-2 – Silva. J Med Virol 2020. doi: 10.1002/jmv.25858. [Online ahead of print].  Back to cited text no. 31
Astuti I, Ysrafil. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr 2020;14:407-12. doi:10.1016/j.dsx.2020.04.020.  Back to cited text no. 32
Hagemeijer MC, Verheije MH, Ulasli M, Shaltiël IA, de Vries LA, Reggiori F, et al. Dynamics of coronavirus replication-transcription complexes. J Virol 2010;84:2134-49.  Back to cited text no. 33
RCSB PDB-6VWW: Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2. Available from: https://www.rcsb.org/structure/6VWW. [Last accessed on 2020 Apr 17].  Back to cited text no. 34
Deng X, Baker SC. An “Old” protein with a new story: Coronavirus endoribonuclease is important for evading host antiviral defenses. Virology 2018;517:157-63.  Back to cited text no. 35
Kim Y, Jedrzejczak R, Maltseva NI, Wilamowski M, Endres M, Godzik A, et al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. Protein Sci 2020;10.1002/pro.3873. doi:10.1002/pro.3873.  Back to cited text no. 36
Subissi L, Posthuma CC, Collet A, Zevenhoven-Dobbe JC, Gorbalenya AE, Decroly E, et al. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc Natl Acad Sci U S A 2014;111:E3900-9.  Back to cited text no. 37
Lehmann KC, Gulyaeva A, Zevenhoven-Dobbe JC, Janssen GM, Ruben M, Overkleeft HS, et al. Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses. Nucleic Acids Res 2015;43:8416-34.  Back to cited text no. 38
Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 2020;368:779-82.  Back to cited text no. 39
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.  Back to cited text no. 40
Yin W, Mao C, Luan X, Shen D-D, Shen Q, Su H, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 2020; eabc1560. doi: 10.1126/science.abc1560. [Online ahead of print].  Back to cited text no. 41


  [Figure 1], [Figure 2], [Figure 3], [Figure 4]

  [Table 1], [Table 2]

This article has been cited by
1 Current Trends and Prospects for Application of Green Synthesized Metal Nanoparticles in Cancer and COVID-19 Therapies
Londiwe Simphiwe Mbatha, Jude Akinyelu, Chika Ifeanyi Chukwuma, Mduduzi Paul Mokoena, Tukayi Kudanga
Viruses. 2023; 15(3): 741
[Pubmed] | [DOI]
2 A Computational Insight on the Inhibitory Potential of 8-Hydroxydihydrosanguinarine (8-HDS), a Pyridone Containing Analog of Sanguinarine, against SARS CoV2**
Atala Bihari Jena, Namrata Kanungo, Gagan Bihari Nityananda Chainy, Vinod Devaraji, Sudipta Kumar Das, Jagneshwar Dandapat
Chemistry & Biodiversity. 2022;
[Pubmed] | [DOI]
3 Mechanistic insights of key host proteins and potential repurposed inhibitors regulating SARS -CoV -2 pathway
Debabrata Pramanik, Aiswarya B. Pawar, Sudip Roy, Jayant Kumar Singh
Journal of Computational Chemistry. 2022;
[Pubmed] | [DOI]
4 Molecular Docking and Dynamics of Phytochemicals From Chinese Herbs With SARS-CoV-2 RdRp
Jingyao Lu, Wenpeng Lu, Houli Jiang, Changshui Yang, Xiaoyun Dong
Natural Product Communications. 2022; 17(6): 1934578X22
[Pubmed] | [DOI]
5 Role of Stress Granules in Suppressing Viral Replication by the Infectious Bronchitis Virus Endoribonuclease
Jing Zhao, Delan Feng, Ye Zhao, Min Huang, Xuehui Zhang, Guozhong Zhang, Rebecca Ellis Dutch
Journal of Virology. 2022;
[Pubmed] | [DOI]
6 Coronavirus Endoribonuclease Ensures Efficient Viral Replication and Prevents Protein Kinase R Activation
Jing Zhao, Lu Sun, Ye Zhao, Delan Feng, Jinlong Cheng, Guozhong Zhang, Kanta Subbarao
Journal of Virology. 2021; 95(7)
[Pubmed] | [DOI]
7 In Silico Molecular Docking and Molecular Dynamic Simulation Analysis of Phytochemicals From Indian Foods as Potential Inhibitors of SARS-CoV-2 RdRp and 3CLpro
Sahar Qazi, Soumi Das, Bharat Krushna Khuntia, Vandna Sharma, Shruti Sharma, Gautam Sharma, Khalid Raza
Natural Product Communications. 2021; 16(9): 1934578X21
[Pubmed] | [DOI]
8 Ayurvedic Medicinal Plants Against COVID-19: An In Silico Analysis
Bharat Krushna Khuntia, Vandna Sharma, Sahar Qazi, Soumi Das, Shruti Sharma, Khalid Raza, Gautam Sharma
Natural Product Communications. 2021; 16(11): 1934578X21
[Pubmed] | [DOI]
9 Yogic Neti-Kriya Using Povidone Iodine: Can it have a Preventive Role Against SARS-CoV-2 Infection Gateway?
Phulen Sarma, Anusuya Bhattacharyya, Ajay Prakash, Hardeep Kaur, Manisha Prajapat, Mukundam Borah, Subodh Kumar, Seema Bansal, Saurabh Sharma, Gurjeet Kaur, Harish Kumar, Dibya Jyoti Sharma, Karuna Kumar Das, Pramod Avti, Bikash Medhi
Indian Journal of Otolaryngology and Head & Neck Surgery. 2021;
[Pubmed] | [DOI]
10 A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing
S. Udhaya Kumar, N. Madhana Priya, S. R. Nithya, Priyanka Kannan, Nikita Jain, D. Thirumal Kumar, R. Magesh, Salma Younes, Hatem Zayed, C. George Priya Doss
3 Biotech. 2021; 11(4)
[Pubmed] | [DOI]
11 Ayurvedic metal nanoparticles could be novel antiviral agents against SARS-CoV-2
Prasanta Kumar Sarkar, Chitrangada Das Mukhopadhyay
International Nano Letters. 2021; 11(3): 197
[Pubmed] | [DOI]
12 Structural and conformational analysis of SARS CoV 2 N-CTD revealing monomeric and dimeric active sites during the RNA-binding and stabilization: Insights towards potential inhibitors for N-CTD
Arushi Chauhan, Pramod Avti, Nishant Shekhar, Manisha Prajapat, Phulen Sarma, Anusuya Bhattacharyya, Subodh Kumar, Hardeep Kaur, Ajay Prakash, Bikash Medhi
Computers in Biology and Medicine. 2021; 134: 104495
[Pubmed] | [DOI]
13 Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors “leflunomide” and “teriflunomide” in Covid-19: A narrative review
Hardeep Kaur, Phulen Sarma, Anusuya Bhattacharyya, Saurabh Sharma, Neeraj Chhimpa, Manisha Prajapat, Ajay Prakash, Subodh Kumar, Ashutosh Singh, Rahul Singh, Pramod Avti, Prasad Thota, Bikash Medhi
European Journal of Pharmacology. 2021; 906: 174233
[Pubmed] | [DOI]
14 Repurposing of Phytomedicine-Derived Bioactive Compounds with Promising Anti-SARS-CoV-2 Potential: Molecular Docking, MD Simulation and Drug-Likeness/ ADMET Studies
Mithun Rudrapal, Neelutpal Gogoi, Dipak Chetia, Johra Khan, Saeed Banwas, Bader Alshehri, Mohammed A. Alaidarous, Umesh D. Laddha, Shubham J. Khairnar, Sanjay G. Walode
Saudi Journal of Biological Sciences. 2021;
[Pubmed] | [DOI]
15 Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2
K.Abraham Peele, Vikas Kumar, Shraddha Parate, Krupanidhi Srirama, Keun Woo Lee, T.C. Venkateswarulu
Journal of Pharmaceutical Sciences. 2021; 110(6): 2346
[Pubmed] | [DOI]
16 Co-expression of the SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in human ovaries: Identification of cell types and trends with age
Meng Wu, Lingwei Ma, Liru Xue, Qingqing Zhu, Su Zhou, Jun Dai, Wei Yan, Jinjin Zhang, Shixuan Wang
Genomics. 2021; 113(6): 3449
[Pubmed] | [DOI]
17 On the Selectivity of Heparan Sulfate Recognition by SARS-CoV-2 Spike Glycoprotein
John E. Chittum, Nehru Viji Sankaranarayanan, Connor P. O’Hara, Umesh R. Desai
ACS Medicinal Chemistry Letters. 2021; 12(11): 1710
[Pubmed] | [DOI]
18 Structural insight into the binding interactions of NTPs and nucleotide analogues to RNA dependent RNA polymerase of SARS-CoV-2
Shruti Koulgi, Vinod Jani, Mallikarjunachari Uppuladinne V N, Uddhavesh Sonavane, Rajendra Joshi
Journal of Biomolecular Structure and Dynamics. 2021; : 1
[Pubmed] | [DOI]
19 Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings
Pramod Avti, Arushi Chauhan, Nishant Shekhar, Manisha Prajapat, Phulen Sarma, Hardeep Kaur, Anusuya Bhattacharyya, Subodh Kumar, Ajay Prakash, Saurabh Sharma, Bikash Medhi
Journal of Biomolecular Structure and Dynamics. 2021; : 1
[Pubmed] | [DOI]
20 An insight into the simulation directed understanding of the mechanism in SARS CoV-2 N-CTD, dimer integrity, and RNA-binding: Identifying potential antiviral inhibitors
Arushi Chauhan, Pramod K. Avti, Nishant Shekhar, Manisha Prajapat, Phulen Sarma, Namrata Sangwan, Jitender Singh, Anusuya Bhattacharyya, Subodh Kumar, Hardeep Kaur, Saurabh Sharma, Ajay Prakash, Bikash Medhi
Journal of Biomolecular Structure and Dynamics. 2021; : 1
[Pubmed] | [DOI]
21 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection
Aleksandra Synowiec, Artur Szczepanski, Emilia Barreto-Duran, Laurensius Kevin Lie, Krzysztof Pyrc
Clinical Microbiology Reviews. 2021; 34(2)
[Pubmed] | [DOI]
22 Deciphering the introduction and transmission of SARS-CoV-2 in the Colombian Amazon Basin
Nathalia Ballesteros, Marina Muñoz, Luz Helena Patiño, Carolina Hernández, Felipe González-Casabianca, Iván Carroll, Mauricio Santos-Vega, Jaime Cascante, Andrés Angel, Alejandro Feged-Rivadeneira, Mónica Palma-Cuero, Carolina Flórez, Sergio Gomez, Adriana van de Guchte, Zenab Khan, Jayeeta Dutta, Ajay Obla, Hala Alejel Alshammary, Ana S. Gonzalez-Reiche, Matthew M. Hernandez, Emilia Mia Sordillo, Viviana Simon, Harm van Bakel, Alberto E. Paniz-Mondolfi, Juan David Ramírez, Camille Lebarbenchon
PLOS Neglected Tropical Diseases. 2021; 15(4): e0009327
[Pubmed] | [DOI]
23 Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase
Matthew R. Freidel, Roger S. Armen, Dennis Salahub
PLOS ONE. 2021; 16(2): e0246181
[Pubmed] | [DOI]
24 Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2
Shruti Koulgi, Vinod Jani, Mallikarjunachari Uppuladinne V. N., Uddhavesh Sonavane, Rajendra Joshi, Chandrabose Selvaraj
PLOS ONE. 2021; 16(5): e0251801
[Pubmed] | [DOI]
25 COVID-19 Protease Inhibitor using Azole N-Mannich Bases: A Molecular Docking Approach
K.N. Arathi, K. Abdul Khayum, Sulaiman Mohammed Alnasser, Onsinyo James Meroka
Asian Journal of Chemistry. 2021; 33(5): 1031
[Pubmed] | [DOI]
26 The Many Faces of Innate Immunity in SARS-CoV-2 Infection
Nicholas Hanan, Ronnie L. Doud, In-Woo Park, Harlan P. Jones, Stephen O. Mathew
Vaccines. 2021; 9(6): 596
[Pubmed] | [DOI]
27 Comparative Safety and Efficacy of Remdesivir Versus Remdesivir Plus Convalescent Plasma Therapy (CPT) and the Effect of Timing of Initiation of Remdesivir in COVID-19 Patients: An Observational Study From North East India
Dibya J Sharma, Aparajita Deb, Phulen Sarma, Bipadabhanjan Mallick, Prithwiraj Bhattacharjee
Cureus. 2021;
[Pubmed] | [DOI]
28 Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines
Yinan Xiao, Hanyue Xu, Wen Guo, Yunuo Zhao, Yuling Luo, Ming Wang, Zhiyao He, Zhenyu Ding, Jiyan Liu, Lei Deng, Fushen Sha, Xuelei Ma
Molecular Biomedicine. 2020; 1(1)
[Pubmed] | [DOI]
29 Letter to the editor: Possible role of topical povidone iodine in case of accidental ocular exposure to SARS-CoV-2
Phulen Sarma, Hardeep Kaur, Bikash Medhi, Anusuya Bhattacharyya
Graefe's Archive for Clinical and Experimental Ophthalmology. 2020; 258(11): 2575
[Pubmed] | [DOI]
30 Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2
Manisha Prajapat, Nishant Shekhar, Phulen Sarma, Pramod Avti, Sanjay Singh, Hardeep Kaur, Anusuya Bhattacharyya, Subodh Kumar, Saurabh Sharma, Ajay Prakash, Bikash Medhi
Journal of Molecular Graphics and Modelling. 2020; 101: 107716
[Pubmed] | [DOI]


Print this article  Email this article


Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow